For US residents only.

New Indication Approved

Ask your doctor about the use of ZYKADIA when you are diagnosed with ALK+ metastatic NSCLC.

Important Safety Information:

ZYKADIA may cause serious side effects, such as:

  • Stomach and intestinal problems ZYKADIA causes stomach and intestinal problems in most people, including diarrhea, nausea, vomiting, and stomach-area pa...

See More
Approved Use:

ZYKADIA® (ceritinib) capsules is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that:

  • Is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body

It is not known if ZYKADIA is safe and effective in children.

about

ZYKADIA

The effectiveness of ZYKADIA® (ceritinib) in these patients is based on a study that measured 2 types of response to treatment (response rate and duration of response). There is no clinical information available to show if patients treated with ZYKADIA live longer or if their symptoms improve. There are ongoing studies to find out how ZYKADIA works over a longer period of time. It is not known if ZYKADIA is safe and effective in children.

Learn More
about

ALK + METASTATIC NSCLC

Advances in genetic research have revealed that non-small cell lung cancer (NSCLC) is not a single disease, but rather many types of cancer with specific genetic differences. Because of these small but important differences, lung cancer medicines that target specific genes, such as anaplastic lymphoma kinase (ALK), can be developed.

Learn More